[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceutical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Biopharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Omeprazole Magnesium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 18, 2023

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Talicia (omeprazole magnesium, amoxicillin and rifabutin) is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics and a proton pump inhibitor (PPI) (omeprazole), used for the treatment of H. pylori infection.

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 01, 2023

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Under the agreement, RedHill will make Talicia, a novel, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole magnesium), approved for H. pylori infection, available via the PhilRx Pat...

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 06, 2023

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Phil

Deal Size : Undisclosed

Deal Type : Agreement

blank

04

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...

Brand Name : Omeprazole Magnesium-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 25, 2022

Lead Product(s) : Omeprazole Magnesium

Therapeutic Area : Gastroenterology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.

Brand Name : Omeprazole Magnesium-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 26, 2022

Lead Product(s) : Omeprazole Magnesium

Therapeutic Area : Gastroenterology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Talicia (Omeprazole Magnesium) efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H. pylori eradicati...

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 25, 2022

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Gaelan Medical will receive the exclusive rights to commercialize Talicia in the UAE, as well as a right of rst refusal to [1] 1 commercialize Talicia in the Gulf Cooperation Council region (Saudi Arabia, Kuwait, Qatar, Bahrain and Oman) for a pre-determ...

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : $2.0 million

January 06, 2022

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Gaelan Medical

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

08

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnes...

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 12, 2021

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Talicia is designed to address the high resistance of H. pylori bacteria to historical standard-of-care therapies. Talicia® is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) with omeprazole magnes...

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 06, 2021

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Pursuant to the agreement, the companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug.

Brand Name : Talicia

Molecule Type : Small molecule

Upfront Cash : Undisclosed

August 13, 2020

Lead Product(s) : Omeprazole Magnesium,Amoxicillin Trihydrate,Rifabutin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Sponsor : Cosmo Pharmaceuticals

Deal Size : $21.0 million

Deal Type : Licensing Agreement

blank